DCTH Delcath Systems (DCTH) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000872912
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
69
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
Delcath Systems insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for DELCATH SYSTEMS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 17, 2023.
- The trade is 7.2% of the 77,018 shares held after it.
- 1 other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Pennell Sandra bought about $50.0K of DCTH on Mar 6, 2026; 1 other insider bought within 30 days and 69 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Nov 11, 2025.
- -7.8% median (-6.2% mean) 90-day return after 8 previous buys.
- The trade is 3.3% of the 342,034 shares held after it.
- 1 other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER MICHEL GERARD J bought about $100.4K of DCTH on Mar 2, 2026, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 69 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 21, 2023.
- The trade is 29.4% of the 14,936 shares held after it.
- 1 other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sylvester John Richard bought about $39.0K of DCTH on Nov 21, 2025; 1 other insider bought within 30 days and 69 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Dec 8, 2023.
- -25.0% median (-9.3% mean) 90-day return after 7 previous buys.
- The trade is 3.5% of the 330,834 shares held after it.
- 1 other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER MICHEL GERARD J bought about $98.1K of DCTH on Nov 11, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 69 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 18, 2022.
- The trade is 2.5% of the 1,069,710 shares held after it.
- 1 other insider bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Aharon Gil bought about $100.0K of DCTH on Mar 19, 2024; 1 other insider bought within 30 days and 69 funds added in the latest 13F quarter.48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
69 funds bought in last quarter
more than 53% of Medical Devices
Revenue
+129.1% year over year
more than 94% of Medical Devices
Margin
3.2% net margin
more than 71% of Medical Devices
Buybacks
$3.0M repurchased, FY to 2026-06-30
below 81% of Medical Devices
Short interest
7.6% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
more than 66% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DCTH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+39.8%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DCTH: institutional holders (13F)
13F holdings, latest reported quarter
3,300,389 sh
$41.6M
2,706,802 sh
$34.1M
1,221,247 sh
$15.4M
871,460 sh
$11.0M
733,115 sh
$9.2M
Congress trades in DCTH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DCTH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DCTH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$3.3M position · as of 2026-06-30
4.3%
NORTH SQUARE KENNEDY MICROCAP FUND
$94.1K position · as of 2026-05-31
0.3%
NORTH SQUARE DYNAMIC SMALL CAP FUND
$2.1M position · as of 2026-05-31
0.3%
ALPS Medical Breakthroughs ETF
$386.1K position · as of 2026-05-31
0.2%
SMALL CAP EQUITY FUND
$1.5M position · as of 2026-06-30
0.1%
BlackRock Advantage Small Cap Growth Fund
$924.2K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
2 active
2
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Gerard Michel
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.8M
$3.1M
$2.0M
+181%
n/a
2024
$2.2M
$4.9M
$1.0M
+234%
n/a
2023
$2.5M
$2.2M
$1.1M
+16%
n/a
2022
$1.5M
-$188.1K
$770.9K
-54%
n/a
2021
$1.9M
-$2.1M
$900.6K
-56%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 69 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DCTH financials
Revenue growth
+129.1%
XBRL, annual
Net margin
3.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$95.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DCTH
| FY Dec 2025 | $85.2M |
| FY Dec 2024 | $37.2M |
| FY Dec 2023 | $2.1M |
| FY Dec 2022 | $2.7M |
| FY Dec 2021 | $3.1M |
| Jun 2026 | $29.1M |
| Mar 2026 | $25.0M |
| Dec 2025 | $20.7M |
| Sep 2025 | $20.6M |
| Jun 2025 | $24.2M |
| Mar 2025 | $19.8M |
| Dec 2024 | $15.1M |
| Sep 2024 | $11.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+0.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DCTH
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | -70.9% |
| FY Dec 2023 | -2,309% |
| FY Dec 2022 | -1,342% |
| FY Dec 2021 | -830.6% |
| Jun 2026 | +9.2% |
| Mar 2026 | -4.3% |
| Dec 2025 | -9.1% |
| Sep 2025 | +4.0% |
| Jun 2025 | +11.2% |
| Mar 2025 | +5.4% |
| Dec 2024 | -22.5% |
| Sep 2024 | +16.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$17.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DCTH
| FY Dec 2025 | $21.0M |
| FY Dec 2024 | -$19.2M |
| FY Dec 2023 | -$31.3M |
| FY Dec 2022 | -$25.2M |
| FY Dec 2021 | -$22.7M |
| Jun 2026 | $5.2M |
| Mar 2026 | $287.0K |
| Dec 2025 | $7.7M |
| Sep 2025 | $4.3M |
| Jun 2025 | $6.9M |
| Mar 2025 | $2.1M |
| Dec 2024 | -$1.2M |
| Sep 2024 | -$3.9M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity DCTH
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.64x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt DCTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -3.08x |
| FY Dec 2022 | -1.59x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -12.93x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+0.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DCTH
| FY Dec 2025 | +3.0% |
| FY Dec 2024 | -62.4% |
| FY Dec 2023 | -961.4% |
| FY Dec 2022 | -1,198% |
| FY Dec 2021 | -150.7% |
| Jun 2026 | +0.5% |
| Mar 2026 | +0.6% |
| Dec 2025 | +3.0% |
| Sep 2025 | +1.9% |
| Jun 2025 | +4.1% |
| Mar 2025 | -30.0% |
| Dec 2024 | -62.4% |
| Sep 2024 | -205.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DCTH
| FY Dec 2025 | +2.7% |
| FY Dec 2024 | -45.8% |
| FY Dec 2023 | -168.8% |
| FY Dec 2022 | -143.2% |
| FY Dec 2021 | -75.7% |
| Jun 2026 | +0.4% |
| Mar 2026 | +0.5% |
| Dec 2025 | +2.7% |
| Sep 2025 | +1.5% |
| Jun 2025 | +3.0% |
| Mar 2025 | -23.0% |
| Dec 2024 | -45.8% |
| Sep 2024 | -86.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 59%, not meaningful
Return on invested capital DCTH
| FY Dec 2025 | +1.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +1.0% |
| Sep 2025 | +13.3% |
| Jun 2025 | +12.7% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DCTH
| FY Dec 2025 | +0.7% |
| FY Dec 2024 | -26.8% |
| FY Dec 2023 | -301.9% |
| FY Dec 2022 | -223.5% |
| FY Dec 2021 | -94.8% |
| Jun 2026 | -1.6% |
| Mar 2026 | -1.7% |
| Dec 2025 | +0.7% |
| Sep 2025 | +9.3% |
| Jun 2025 | +7.8% |
| Mar 2025 | -2.8% |
| Dec 2024 | -26.8% |
| Sep 2024 | -122.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
1,451.00x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing DCTH
| FY Dec 2025 | 144.29x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 1,259.00x |
| Mar 2026 | 928.00x |
| Dec 2025 | 144.29x |
| Sep 2025 | 358.33x |
| Jun 2025 | 194.29x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$456.0M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value DCTH
| FY Dec 2025 | $313.2M |
| FY Dec 2024 | $352.6M |
| FY Dec 2023 | $89.2M |
| FY Dec 2022 | $39.0M |
| FY Dec 2021 | n/a |
| Jun 2026 | $387.1M |
| Mar 2026 | $281.1M |
| Dec 2025 | $313.2M |
| Sep 2025 | $334.2M |
| Jun 2025 | $439.2M |
| Mar 2025 | $412.4M |
| Dec 2024 | $352.6M |
| Sep 2024 | $246.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield DCTH
| FY Dec 2025 | +5.9% |
| FY Dec 2024 | -5.0% |
| FY Dec 2023 | -34.1% |
| FY Dec 2022 | -81.3% |
| FY Dec 2021 | -39.9% |
| Jun 2026 | +4.0% |
| Mar 2026 | +6.0% |
| Dec 2025 | +5.9% |
| Sep 2025 | +3.2% |
| Jun 2025 | +0.8% |
| Mar 2025 | -1.8% |
| Dec 2024 | -5.0% |
| Sep 2024 | -10.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -86%, PEG needs growth
PEG, trailing DCTH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $85.2M | $37.2M | $2.1M | $2.7M |
| Gross profit | $73.4M | $31.0M | $1.4M | $2.0M |
| Operating income | $660.0K | -$12.4M | -$38.2M | -$33.9M |
| Net income | $2.7M | -$26.4M | -$47.7M | -$36.5M |
| EPS (diluted) | 0.07 | -0.93 | -2.94 | -4.12 |
| Operating cash flow | $22.5M | -$18.7M | -$31.3M | -$24.9M |
| Cash | $43.5M | $32.4M | $12.6M | $7.7M |
| Long-term debt | n/a | $0 | $10.2M | $15.7M |
| Buybacks | $6.0M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
DCTH Stock Sonar score 5/7 axes
Find similar shapesCompareDCTH ranks highest on financial health (99th percentile) and growth (94th), and lowest on institutional and government (34th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
